Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. - Wikidata - wikimedia - TriplyDB

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

http://www.wikidata.org/entity/Q34415510

about

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer Radiotherapy combination opportunities leveraging immunity for the next oncology practice Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials Immunological interactions in radiotherapy-opening a new window of opportunity Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities Therapeutic cancer vaccines: past, present, and future A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy Radiation meets immunotherapy - a perfect match in the era of combination therapy?Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines Combining radiotherapy and cancer immunotherapy: a paradigm shift In situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancer Current clinical trials testing the combination of immunotherapy with radiotherapy.Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients.Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions Advances in preclinical investigation of prostate cancer gene therapy.CpG Oligodeoxynucleotides Enhance the Activities of CD8+ Cytotoxic T-Lymphocytes Generated by Combined hMUC1 Vaccination and hNIS Radioiodine Gene Therapy.Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer Vaccines against human carcinomas: strategies to improve antitumor immune responses.Vaccines as monotherapy and in combination therapy for prostate cancer.Monoclonal antibodies: versatile platforms for cancer immunotherapy.Cancer immunotherapy: sipuleucel-T and beyond.Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways.Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.The tumor-immune microenvironment and response to radiation therapy Combinations of immunotherapy and radiation in cancer therapy.The combination of ANT2 shRNA and hNIS radioiodine gene therapy increases CTL cytotoxic activity through the phenotypic modulation of cancer cells: combination treatment with ANT2 shRNA and I-131 Exploiting synergy: immune-based combinations in the treatment of prostate cancer.Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells (R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment Prostate cancer as a model for tumour immunotherapy.Viral vector-based therapeutic cancer vaccines Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.

P2860

Q24602728-7049A96C-1B25-40BF-AF98-D652B6D92F88 Q24655036-584F5F64-F09E-4BCD-86C2-78945DC2CA9E Q24684241-C0395D48-1945-4485-A080-0C3AF6B83EED Q26738443-BB76DF9E-894A-49A2-8D68-AC05B0F37333 Q26765115-31EFDB4C-9ECC-4AD3-BA1B-1C330523E7BB Q26767178-7A1929C5-6DCA-4AC3-BBE8-F9EDB543B7D4 Q26825053-00F8AD5F-8BB3-4792-8DFE-544564854AE0 Q26827475-15439497-12CB-46ED-BFAD-75E8A8BC737E Q26851710-E6B4A27F-BA14-4954-BA4C-DE65A6E5493D Q26863283-736878F8-3E8D-4223-A5CD-9E69D80CC496 Q27000180-FC12F0B6-4F47-48C8-86CA-A5130F905C90 Q27001216-130DA8D7-7778-4BDC-8C0B-8F994BAF0D00 Q27005913-C8C3FACC-9710-4E58-B8C2-7D05F536FCEB Q27008070-8153AD53-463B-4A7C-9BE0-BD548294C028 Q27021428-682E18C3-F5F0-4A3A-AA72-898B12FBFBE0 Q28390899-5DB34C3A-F003-46EB-86F3-9D146ED167CD Q30356447-2D1D63A9-35F7-416D-B84F-527416346B53 Q30408302-43C0255E-C2F7-49B2-8143-AA7C3E7269FB Q33275987-EE53DE56-19B1-4633-9A72-7A516DF7E507 Q33609458-81D91A36-E4A5-40D0-AAD1-77D0A2E5CF40 Q33621393-AFB638D5-FE8C-40A3-9E09-BAD5C36E1FA1 Q33627023-F3810387-F682-4064-8F6B-095F7696F131 Q33677054-ED919C1C-85EB-4459-84B5-0CAA133EAD89 Q33704106-B7528533-EBF7-4E9E-96BB-16C4E45AE5A1 Q33712858-94F5BEB3-B682-445F-9793-118C470192F9 Q33734281-72DEC3FC-F027-4D85-81EF-11FC924CFAC8 Q34039068-235E891F-8F02-4E48-B703-3521C975EB01 Q34111693-CB5B6789-BEB5-4C23-BE19-E363611156E1 Q34158070-A92FA137-94F7-4EC9-B2DC-4F6C6EB7B37B Q34184469-6F4F7A70-04E3-41BE-A353-9912E228239A Q34333155-F121A14C-9340-4385-893D-1932EE6EEAB6 Q34444598-D2D3C7C9-1D25-4E7A-B036-BF4072E21A9B Q34582640-CD3F86B8-2D8E-4152-876D-2EC21D62EB99 Q34632674-0A971CE7-7A3E-4650-9918-95B781EF81D5 Q34687216-445CF2E7-7210-4081-A26F-A80C853456F5 Q34698158-6CBF7DB7-43E4-4335-A136-B807F0BEC38A Q34736597-FA1FE03E-F925-48AB-AA33-A3C373D82B19 Q34856875-C262C280-C5AC-497C-B0FD-522A8767C6B5 Q35515080-52A4FD93-81D2-4E49-9C91-12D56F527601 Q35562729-2ADE5376-04D6-4E2C-9EE9-5CA3B44232FF

P2860

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.

http://www.wikidata.org/entity/Q34415510

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Combining a recombinant cancer ...... ith localized prostate cancer.

@ast

Combining a recombinant cancer ...... ith localized prostate cancer.

@en

Combining a recombinant cancer ...... ith localized prostate cancer.

@nl

type

label

Combining a recombinant cancer ...... ith localized prostate cancer.

@ast

Combining a recombinant cancer ...... ith localized prostate cancer.

@en

Combining a recombinant cancer ...... ith localized prostate cancer.

@nl

prefLabel

Combining a recombinant cancer ...... ith localized prostate cancer.

@ast

Combining a recombinant cancer ...... ith localized prostate cancer.

@en

Combining a recombinant cancer ...... ith localized prostate cancer.

@nl

P1433

Q34415510-03086EEE-B6FB-4550-BDF9-40ABEE46805B

P1476

Q34415510-10B8AD32-B4AB-429F-A938-30234284BBDF

P2093

Q34415510-32C68366-35C8-4DE9-8E04-40130365D56E

Q34415510-37D4027B-E7D8-41FB-A5CA-0E6E9F813BEC

Q34415510-51408788-5340-48B0-A658-29150D14A14B

Q34415510-60FACD8C-1075-42F8-8D38-2EE71B8CB893

Q34415510-6C6E8C7F-609A-42F7-AB8B-153BE729C23D

Q34415510-7C8ADF16-4185-4103-887D-CD36C188B97E

Q34415510-842D89A4-1592-4AFC-8759-B45B3D6B412E

Q34415510-8861BBDA-437A-4404-BC62-50FD28901FB0

Q34415510-B13E2CEA-803D-4D88-A2CA-53C0104AFA82

Q34415510-BFF3F0C4-6044-4E25-A006-F9793430F917

P304

Q34415510-15E42431-5F35-4361-9241-62D276EF32C0

P31

Q34415510-AD1C4B6D-517E-4EC9-BE56-DDF3B6A15D92

P356

Q34415510-476E9D2F-C3DD-4692-8AC0-BECB7FBD0CF6

P407

Q34415510-6C29D26D-65B2-4E2B-B395-05B0C25AD1E5

P433

Q34415510-9A461BED-9F30-449D-B091-B0AA9C80D732

P478

Q34415510-64FC0F2E-75E0-4726-BCFD-311E6C8E97C3

P50

Q34415510-75B6CBC4-8A48-46D6-9A10-E25086C8DAC3

P577

Q34415510-3216D47B-15F1-4DF4-89EF-93439A68B0BD

P5875

Q34415510-1D74D8F3-575F-4B59-84A0-42E69EE40D08

P698

Q34415510-0E31CED4-F2F9-4519-BAFC-0BF3DC358904

P921

Q34415510-F98E011C-0802-4163-95A4-77187A39C5E6

P356

1078-0432.CCR-04-2062

P1433

Clinical Cancer Research

P1476

Combining a recombinant cancer ...... ith localized prostate cancer.

@en

P2093

Anne Bastian

http://www.w3.org/2001/XMLSchema#string

C Norman Coleman

http://www.w3.org/2001/XMLSchema#string

Cynthia Ménard

http://www.w3.org/2001/XMLSchema#string

James L Gulley

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

Jeffrey Schlom

http://www.w3.org/2001/XMLSchema#string

Jennifer Marte

http://www.w3.org/2001/XMLSchema#string

Junko Yokokawa

http://www.w3.org/2001/XMLSchema#string

Kevin Camphausen

http://www.w3.org/2001/XMLSchema#string

Kwong-Yok Tsang

http://www.w3.org/2001/XMLSchema#string

P304

3353-3362

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-04-2062

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Francis J. Sullivan

P577

2005-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7871529

http://www.w3.org/2001/XMLSchema#string

P698

15867235

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy